There has been a growing trend of life science manufacturers collaborating with local governments (e.g., at the municipal and prefectural level) in Japan during the past 3-5 years. This trend is observed not only with domestic manufacturers but among foreign…
HOME > BUSINESS
BUSINESS
- Chugai Gets Priority Review for PNH Med Crovalimab in China
August 12, 2022
- Sumitomo Pharma to Rev Up R&D for Regenerative Medicine, CNS towards Later 2030s
August 12, 2022
- Japan Ethical Drug Sales Inch Up 1.1% in June: Crecon
August 12, 2022
- AbbVie Seeks Crohn’s Disease Nod for Rinvoq in Japan
August 12, 2022
- Shionogi’s COVID Pill Shows In Vitro Antiviral Activity Against BA.2.75
August 12, 2022
- PeptiDream and RayzeBio Expand Alliance on Peptide-Radiotherapeutics
August 12, 2022
- Eisai, Lifenet Insurance Enter Capital, Biz Tie-Up to Build Dementia Ecosystem
August 12, 2022
- Opdivo Tops Japan Drug Sales Ranking 7 Months Running: Encise July Data
August 12, 2022
- Moderna Files Omicron Bivalent Vaccine in Japan
August 10, 2022
- Sumitomo Drops 100 Billion Yen Diabetes Sales Goal as Trulicity Collab Ends
August 10, 2022
- Nipro Eyes 60% AG Share in Nexium Generic Market: Exec
August 10, 2022
- Daiichi Sankyo’s HER3 ADC Enters PIII for EGFR-Mutated NSCLC
August 10, 2022
- Kirin Looking to Develop Lactococcus Lactis-Based COVID-19 Drug
August 10, 2022
- Yen’s Fall Reaps 10 Billion Yen-Plus Gain on Sales for 5 Japan Makers, Takeda Gets 8.8 Billion Yen: April-June
August 9, 2022
- Pfizer Seeks Japan Nod for Omicron-Adapted Bivalent Jab
August 9, 2022
- Myfembree Snags Endometriosis Nod in US: Myovant/Pfizer
August 9, 2022
- Maruho’s Mitchga Now Available for Eczema Itching in Japan
August 9, 2022
- Chugai Settles Patent Suit against Fresenius Kabi over Alecensa
August 9, 2022
- Enhertu Grabs US Approval for HER2 Low Breast Cancer: Daiichi Sankyo/AZ
August 9, 2022
- Incyte Files Pemazyr for Myelogenous/Lymphatic Tumor in Japan
August 9, 2022
ページ
Shionogi’s COVID-19 pill ensitrelvir failed to clear the second round of review by a key advisory panel on July 20. The session drew a great deal of attention since the drug is the first candidate for the application of Japan’s…
The average ratio of females in managerial posts at Japanese drug makers has finally reached a double-digit number, at 10.0%, a Jiho survey found. However, this is still well below a near-25% ratio logged by foreign players operating in the…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…
A total of 15 new drugs (APIs) joined the NHI price list in 2021 with peak sales forecasts topping at 10 billion yen, many of them in the area of orphan diseases and with few mega launches, according to a…